Written by Dr. Suegee Tamar-Mattis, Medical Director
Today I’d like to take a deeper dive into MDMA and its potential role in the treatment of PTSD. Many people are curious about what happens in the brain when someone takes MDMA (also called Ecstasy)—and what the experience actually feels like.
One of the first things scientists believe happens is that MDMA causes a large release of a neurotransmitter called serotonin, along with increases in dopamine and norepinephrine. Serotonin is thought to play an important role in the deep feelings of empathy, emotional warmth, and connection that many people experience during an MDMA session.
These effects are why MDMA is often described as an empathogen or entactogen—a substance that can enhance feelings of emotional closeness and connection. These qualities may also help explain why researchers have been interested in MDMA as a treatment for PTSD.
The increases in dopamine and norepinephrine contribute to heightened alertness, energy, and engagement with the therapeutic process. MDMA also stimulates the release of hormones such as oxytocin (sometimes called “the love hormone”), which may strengthen feelings of trust, safety, and social bonding.
When these effects come together, many people describe feeling deeply connected—to themselves, to their therapist, and to the people who matter most in their lives. They often report feeling less anxious or self-conscious, more emotionally open, and more willing to talk about experiences that previously felt overwhelming or impossible to revisit.
Researchers believe this unique psychological state may allow people with PTSD to revisit traumatic memories in a safer emotional context. Instead of being overwhelmed by fear, shame, or avoidance, they may be able to process these memories with greater self-compassion, curiosity, and emotional resilience.
When I completed my nine-month Certification in Psychedelic-Assisted Therapies and Research at the California Institute of Integral Studies (CIIS), we also received specialized training in MDMA-assisted therapy through the Multidisciplinary Association for Psychedelic Studies (MAPS). As part of that training, we spent many hours observing recordings of MDMA therapy sessions conducted during clinical research trials. The researchers walked us through the participants’ experiences while explaining both the medical and psychological aspects of the treatment.
For me, this was one of the most profound parts of my training. Watching participants move through fear, grief, and trauma with such openness left me with a deep sense of hope. While MDMA-assisted therapy is still working its way through the regulatory process, the research to date suggests it has the potential to become an important new option for people living with PTSD.
As a clinician, I am looking forward to the day when we will be able to work with this medicine outside of the research setting. Many of LIminal’s providers are trained in MDMA-assisted therapy, and we are following the legalization process closely so that we will be prepared to offer it as soon as it is approved.